Avatrombopag in immune thrombocytopenia and beyond: Current evidence and emerging perspectives
{{output}}
Immune thrombocytopenia (ITP) is a rare autoimmune disorder characterized by reduced platelet counts, increased bleeding risk, and impaired quality of life. Thrombopoietin receptor agonists are established second-line therapies; among these, avatrombopag is an... ...